FAK-heterozygous mice display enhanced tumour angiogenesis.
about
FAK in cancer: mechanistic findings and clinical applicationsCell cycle-dependent Rho GTPase activity dynamically regulates cancer cell motility and invasion in vivoTumour-associated endothelial-FAK correlated with molecular sub-type and prognostic factors in invasive breast cancer.FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and MetastasisAnti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumorsTIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway.Targeting FAK in human cancer: from finding to first clinical trials.Focal Adhesion Kinase (FAK) tyrosine 397E mutation restores the vascular leakage defect in endothelium-specific FAK-kinase dead mice.Molecular Pathways: Endothelial Cell FAK-A Target for Cancer Treatment.Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy.FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes.Exploring the Role of RGD-Recognizing Integrins in Cancer.Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3.The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer
P2860
Q27026533-38BAB38A-C4B6-4B75-8438-8B3881E8F8D0Q27339470-79E47A28-9514-41D4-A28F-3E46729D2DF7Q35137962-97310455-B18E-48D6-8032-56FB4A2875ACQ35558306-24A04D63-8B47-4625-AC4B-989818382C15Q35832582-AF3740F6-6763-4259-858E-88BE06118294Q36296805-CB9B7840-3299-430F-9D48-10B2889E18D0Q37267647-0F5D1BE8-2640-41BA-B186-CF5A183FC902Q38175738-B5EF40B7-26A5-4E92-9DB0-177EE44E62B0Q38706013-36D3AF9E-574B-4A77-8798-BE0161D03C91Q38854580-48005486-D5CE-4983-A3AF-D92420671D7BQ38989530-2EAE0504-ED27-4EE6-AFD8-515D6C6ED3A5Q39711361-F3E2891B-B247-4BF2-AA03-30F10B9DB07DQ41670915-7AD259EB-2989-4E20-90BB-2FAA40A3289BQ47600958-94D35CF6-2A9C-42A3-8189-BC23142C1D4AQ58712101-8961524D-89DF-4382-8C41-8A6435FD85AA
P2860
FAK-heterozygous mice display enhanced tumour angiogenesis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
FAK-heterozygous mice display enhanced tumour angiogenesis.
@en
FAK-heterozygous mice display enhanced tumour angiogenesis.
@nl
type
label
FAK-heterozygous mice display enhanced tumour angiogenesis.
@en
FAK-heterozygous mice display enhanced tumour angiogenesis.
@nl
prefLabel
FAK-heterozygous mice display enhanced tumour angiogenesis.
@en
FAK-heterozygous mice display enhanced tumour angiogenesis.
@nl
P2093
P2860
P50
P356
P1476
FAK-heterozygous mice display enhanced tumour angiogenesis.
@en
P2093
Anna M Randi
Antoine R Ramjaun
Bernardo Tavora
Delphine M Lees
Dylan T Jones
Ian R Hart
Kairbaan Hodivala-Dilke
Louise E Reynolds
Marianne Baker
Tanguy Lechertier
P2860
P2888
P356
10.1038/NCOMMS3020
P407
P577
2013-01-01T00:00:00Z